CHOSA Oncology AB out-license clinical-stage cancer vaccine candidate to Magle Group
CHOSA Oncology AB, today announces that the company has out-licensed the clinical-stage therapeutic cancer vaccine candidate onilcamotide to Magle Group. Magle Group plans to further develop onilcamotide by use of its proprietary degradable starch microspheres (DSM) technology. The company sees a future potential to combine onilcamotide treatment with its already approved vascular embolic product EmboCept® S.
Onilcamotide is a clinical-stage therapeutic cancer vaccine candidate targeting RhoC, an over-expressed protein in metastatic cancer cells. Onilcamotide is a peptide that forms a fragment of RhoC, and when introduced into the body, it triggers the immune system to attack the cells that overexpress RhoC.
“We have identified an interesting opportunity to exploit synergies between onilcamotide, our in-house DSM technology, and our already approved chemoembolization product EmboCept S. Through limited and responsible investments, we will now initiate activities with the aim to establish proof-of-concept for a reformulated version of onilcamotide. This constitutes an important first step in our long-term aim of bringing the drug candidate towards a potential marketing approval for a niche indication,“ says Justin Pierce, CEO of Magle Group.
CHOSA Oncology’s CEO, Peter Buhl comments: “With the out-licensing of Onilcamotide to Magle Group I believe the asset has found the right home for successful development. Onilcamotide is an asset CHOSA's got from the RhoVac acquisition. The deal includes a royalty agreement. We wish Magle good luck and success with unlocking the value of the asset”
Under the licensing agreement, which covers onilcamotide and related intellectual properties, CHOSA Oncology AB will receive an upfront payment to recover costs related to patent fees. Magle Group shall take over the patent maintenance alongside a royalty obligation following the potential future commercialization of the product.
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-05-2023 11:02 CET.
For additional information contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio
+ 45 21 60 89 22
Justin Pierce, CEO
justin.pierce@maglechemoswed.com
+46 (0)70 593 58 21
About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of iCIP™.
About iCIP™
CHOSA is focused on late-stage clinical development of iCIP™ (LiPlaCis® and its DRP® companion diagnostic together) to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Even when lung cancer surgery is successful in removing all visible tumor, too many patients have a re-emergence of cancer. Cisplatin therapy after surgery is a gold standard that clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Tissue from the patient’s lung cancers was tested with the cisplatin DRP technology to get the DRP scores. A high cisplatin DRP score was directly linked to high cisplatin efficacy. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA.
LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.